Table 1.
Univariate and Multivariate Analysis of Factors Associated with Overall Survival of Patients with TSCC
| Variable | Cases Number | HR (95% CI) | P |
|---|---|---|---|
| Univariate Analysis | |||
| Sex Male vs female |
62/51 | 1.107(0.604–2.030) | 0.604 |
| Age(years) <50 vs ≥50 |
37/76 | 1.186(0.739–1.904) | 0.593 |
| Node metastasis N0 vs N+ |
47/66 | 1.579(1.169–2.132) | 0.023 |
| Clinical stage III VS IV |
70/43 | 2.040(1.368–3.041) | <0.001 |
| Cisplatin Sensitive vs non-sensitive |
61/52 | 0.708(0.509–0.986) | 0.046 |
| CISAL Low vs high |
46/67 | 1.687(1.207–2.357) | 0.011 |
| BRCA1 Low vs high |
71/42 | 1.716(1.207–2.439) | 0.009 |
| Multivariate Analysis | |||
| Node metastasis N0 vs N+ |
47/66 | 1.686(1.328–2.140) | 0.014 |
| Clinical stage III VS IV |
70/43 | 2.119(1.374–3.269) | <0.001 |
| Cisplatin Sensitive vs non-sensitive |
61/52 | 0.667(0.496–0.896) | 0.032 |
| CISAL Low vs high |
46/67 | 1.820(1.306–2.537) | 0.002 |
| BRCA1 Low vs high |
71/42 | 1.862(1.269–2.731) | <0.001 |